Needham Reiterates Merus N.V (MRUS) Buy Recommendation
Fintel reports that on June 30, 2023, Needham reiterated coverage of Merus N.V (NASDAQ:MRUS) with a Buy recommendation.
Analyst Price Forecast Suggests 77.37% Upside
As of June 2, 2023, the average one-year price target for Merus N.V is 46.61. The forecasts range from a low of 35.35 to a high of $51.45. The average price target represents an increase of 77.37% from its latest reported closing price of 26.28.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Merus N.V is 41MM, a decrease of 5.04%. The projected annual non-GAAP EPS is -3.45.
What is the Fund Sentiment?
There are 160 funds or institutions reporting positions in Merus N.V. This is an increase of 6 owner(s) or 3.90% in the last quarter. Average portfolio weight of all funds dedicated to MRUS is 0.60%, an increase of 30.54%. Total shares owned by institutions decreased in the last three months by 1.44% to 38,847K shares. 
The put/call ratio of MRUS is 0.97, indicating a bullish outlook.
What are Other Shareholders Doing?
Wellington Management Group Llp holds 3,137K shares representing 6.74% ownership of the company. In it's prior filing, the firm reported owning 3,690K shares, representing a decrease of 17.63%. The firm decreased its portfolio allocation in MRUS by 0.07% over the last quarter.
Bvf holds 2,978K shares representing 6.40% ownership of the company. No change in the last quarter.
Commodore Capital holds 2,950K shares representing 6.34% ownership of the company. In it's prior filing, the firm reported owning 2,733K shares, representing an increase of 7.37%. The firm increased its portfolio allocation in MRUS by 29.72% over the last quarter.
Federated Hermes holds 2,639K shares representing 5.67% ownership of the company. In it's prior filing, the firm reported owning 3,924K shares, representing a decrease of 48.72%. The firm decreased its portfolio allocation in MRUS by 60.04% over the last quarter.
Deerfield Management Company, L.p. holds 2,380K shares representing 5.12% ownership of the company. No change in the last quarter.
Merus N.V Background Information
(This description is provided by the company.)
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity.
Key filings for this company:
This story originally appeared on Fintel.